Protein Binding of Drugs

Oral Bioavailability: Basic Principles, Advanced Concepts, and Applications

Volumn , Issue , 2011, Pages 145-166

  Kotsiou, Antonia ^a   Tesseromatis, Christine ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Diseases, influencing drug protein binding plasma proteins levels, altered in disease states; Drug protein binding, physicochemical interactions drugs, and silent transporter molecules; Protein and tissue binding, on pharmacokinetic parameters volume of distribution

Indexed keywords

EID: 84885829171     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118067598.ch11     Document Type: Chapter

References (148)

1. Ascenzi P, Bocedi A, Notari S, Fanali G, Fesce R, and Fasano M (2006) Allosteric modulation of drug binding to human serum albumin. Mini Rev Med Chem 6(4):483-489.
2. Bachmann K, Shapiro R, and Mackiewicz J (1976) Influence of renal dysfunction on warfarin plasma protein binding. J Clin Pharmacol 16(10 Pt 1):468-472.
3. Baker ME (2002) Albumin, steroid hormones and the origin of vertebrates. J Endocrinol 175(1):121-127.
4. Ballantyne FC, Fleck A, and Dick WC (1971) Albumin metabolism in rheumatoid arthritis. Ann Rheum Dis 30(3): 265-270.
5. Benkestock K, Edlund PO, and Roeraade J (2005) Electrospray ionization mass spectrometry as a tool for determination of drug binding sites to human serum albumin by noncovalent interaction. Rapid Commun Mass Spectrom 19(12):1637-1643.
6. Bhattacharya AA, Curry S, and Franks NP (2000) Binding of the general anesthetics propofol and halothane to human serum albumin: high-resolution crystal structures. J Biol Chem 275:38731-38738.
7. Bhattacharya AA, Grüne T, and Curry S (2000) Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J Mol Biol 303:721-732.
8. Bickel MH and Gerny R (1980) Drug distribution as a function of binding competition. Experiments with the distribution dialysis technique. J Pharm Pharmacol 32:669-674.
9. Birkett DJ, Myers SP, and Sudlow G (1977) Effects of fatty acids on two specific drug binding sites on human serum albumin. Mol Pharmacol 13(6):987-992.
10. Blaschke TF (1977) Protein binding and kinetics of drugs in liver diseases. Clin Pharmacokinet 2(1):32-44.
11. Boobis AR, Brodie MJ, Davies DS, Fletcher DR, and Saunders JH (1978) Mixed function oxidase activity in microsomal fractions of human liver biopsy specimens. Br J Clin Pharmacol 6(5): 449P-450P.
12. Brunner M and Langer O (2006) Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution. AAPS J 8(2): E263-E271.
13. Brunner M and Móller M (2002) Microdialysis: an in vivo approach for measuring drug delivery in oncology. Eur J Clin Pharmacol 58:227-234.
14. 13C nuclear magnetic resonance study. J Clin Invest 87:1431-1441.
15. Clausen J and Bickel MH (1993) Prediction of drug distribution in distribution dialysis and in vivo from binding to tissues and blood. J Pharm Sci 82(4):345-349.
16. Craig WA and Suh B (1978) Changes in protein binding during disease. Scand J Infect Dis Suppl 14:239-244.
17. Creedon KA and Suttie JW (1986) Effect of N-methylthiotetrazole on vitamin K epoxide reductase. Thromb Res 44(2):147-153.
18. Curry S, Brick P, and Franks NP (1999) Fatty acid binding to human serum albumin: new insights from crystallographic studies. Biochim Biophys Acta 1441:131-140.
19. Curry S, Mandelkow H, Brick P, and Franks N (1998) Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol 5:827-835.
20. David BM, Ilett KF, Whitford EG, and Stenhouse NS (1983) Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction. Br J Clin Pharmacol 15(4):435-441.
21. de la Pena A, Liu P, and Derendorf H (2000) Microdialysis in peripheral tissues. Adv Drug Deliv Rev 45:189-216.
22. Delbono O, Xia J, Treves S, Wang ZM, Jimenez-Moreno R, Payne AM, Messi ML, Briguet A, Schaerer F, Nishi M, Takeshima H, and Zorzato F (2007) Loss of skeletal muscle strength by ablation of the sarcoplasmic reticulum protein JP45. Proc Natl Acad Sci USA 104(50):20108-20113.
23. Dhillon HS, Dose JM, Scheff SW, and Prasad MR (1997) Time course of changes in lactate and free fatty acids after experimental brain injury and relationship to morphologic damage. Exp Neurol 146(1):240-249.
24. du Souich P, Verges J, and Erill S (1993) Plasma protein binding and pharmacological response. Clin Pharmacokinet 24(6):435-440.
25. Engelhardt G (1978) Effect of non-steroidal anti-inflammatory drugs on plasma protein binding of corticosterones. Arzneimittelforschung 28(10):1714-1723.
26. Fichtl B (1990) The influence of renal failure on-drug binding in plasma and tissues. Nieren-und Hochdruckkrank-Heiten 19(10):447-449.
27. Fichtl B and Kurz H (1978) Binding of drugs to human muscle. Eur J Clin Pharmacol 14(5):335-340.
28. Fichtl B, Meister W, and Schmied R (1983) Serum protein binding of drugs is not altered in patients with severe chronic cardiac failure. Int J Clin Pharmacol Ther Toxicol 21(5):241-244.
29. Fichtl B, Niecieki A, and Walter K (1991) Tissue binding versus plasma binding of drugs: general principles and pharmacokinetic consequences. Adv Drug Res 20:118-160.
30. Fiset C, Vallée F, LeBel M, and Bergeron MG (1986) Protein binding of ceftriaxone: comparison of three techniques of determination and the effect of 2-hydroxybenzoylglycine, a drugbinding inhibitor in uremia. Ther Drug Monit 8(4):483-489.
31. Foye WO (1998) Principles of Medicinal Chemistry. 3rd ed. Lea and Febiger, Philadelphia, PA, p. 33.
32. Frey BM, Hugentobler T, Bührer M, and Frey FJ (1984) Transcortin concentrations in the plasma of normal persons and patients with kidney and liver diseases. Klin Wochenschr 62(19):936-938.
33. Gatti G, Crema F, Attardo-Parrinello G, Fratino P, Aguzzi F, and Perucca E (1987) Serum protein binding of phenytoin and valproic acid in insulin-dependent diabetes mellitus. Ther Drug Monit 9(4):389-391.
34. Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, and Curry S (2005) Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol 353:38-52.
35. Giacomini KM, Massoud N, Wong FM, and Giacomini JC (1984) Decreased binding of verapamil to plasma proteins in patients with liver disease. J Cardiovasc Pharmacol 6(5):924-928.
36. Giamarellos-Bourboulis EJ, Mouktaroudi M, Adamis T, Koussoulas V, Baziaka F, Perrea D, Karayannacos PE, and Giamarellou H (2004) n-6 Polyunsaturated fatty acids enhance the activities of ceftazidime and amikacin in experimental sepsis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 48(12):4713-4717.
37. Gibaldi A (1977) Drug distribution in renal failure. Am J Med 62(4):471-474.
38. Gillette JR (1971) Factors affecting drug metabolism. Ann N Y Acad Sci 179:43-66.
39. Gillis AM and Kates RE (1986) Influence of protein binding on the myocardial uptake and pharmacodynamics of propafenone. J Cardiovasc Pharmacol 8(6):1163-1167.
40. Griffiths JR and Glickson JD (2000) Monitoring pharmacokinetics of anticancer drugs: non-invasive investigation using magnetic resonance spectroscopy. Adv Drug Deliv Rev 41:75-89.
41. Grossman SH, Davis D, Kitchell BB, Shand DG, Routledge PA (1982) Diazepam and lidocaine plasma protein binding in renal disease. Clin Pharmacol Ther 31(3):350-357.
42. Gupta N, Price PM, and Aboagye EO (2002) PET for in vivo pharmacokinetic and pharmacodynamic measurements. Eur J Cancer 38:2094-2107.
43. Habig WH, Pabst MJ, Fleischner G, Gatmaitan Z, Arias IM, and Jakoby WB (1974) The identity of glutathione S-transferase B with ligandin, a major binding protein of liver. Proc Natl Acad Sci USA 71(10):3879-3882.
44. Hamilton JA, Era S, Bhamidipati SP, and Reed RG (1991) Locations of the three primary binding sites for long-chain fatty acids on bovine serum albumin. Proc Natl Acad Sci USA 88:2051-2054.
45. He XM and Carter DC (1992) Atomic structure and chemistry of human serum albumin. Nature 358:209-215.
46. Hill MD and Abramson FP (1988) The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady-state. Clin Pharmacokinet 14(3):156-170.
47. Holladay JW, Dewey MJ, Michniak BB, Wiltshire H, Halberg DL, Weigl P, et al. (2001) Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. Drug Metab Dispos 29(3):299-303.
48. Hu OY, Chu KM, Liu HS, Chiao SF, Ho W, and Ho ST (1993) Reinduction of the hypnotic effects of thiopental with NSAIDs by decreasing thiopental plasma protein binding in humans. Acta Anaesthesiol Scand 37(3):258-261.
49. Huang BX, Dass C, and Kim HY (2005) Probing conformational changes of human serum albumin due to unsaturated fatty acid binding by chemical cross-linking and mass spectrometry. Biochem J 387(Pt 3):695-702.
50. Ivarsen R and Broderson R (1989) Displacement of bilirubin from adult and newborn serum albumin by a drug and fatty acid. Dev Pharmacol Ther 12(1):19-29.
51. Jacobi J, McGory RW, McCoy H, and Matzke GR (1983) Hemodialysis clearance of total and unbound lidocaine. Clin Pharm 2(1):54-57.
52. Joukhadar C, Derendorf H, and Móller M (2001) Microdialysis: a novel tool for clinical studies of anti-infective agents. Eur J Clin Pharmacol 57:211-219.
53. Jutila A, Rytomaa M, and Kinnunen PK (1998) Detachment of cytochrome c by cationic drugs from membranes containing acidic phospholipids: comparison of lidocaine, propranolol, and gentamicin. Mol Pharmacol 54(4):722-732.
54. Karakitsos D, Andreas K, and Antonia K (2009) Changes of lidocaine levels in rat serum and tissue under stress and hyperlipidemic diets. Eur J Drug Metab Pharmacokinet 34(3-4):143-146.
55. Kearns GL, Kemp SF, Turley CP, and Nelson DL (1988) Protein binding of phenytoin and lidocaine in pediatric patients with type I diabetes mellitus. Dev Pharmacol Ther 11(1):14-23.
56. Kemp SF, Kearns GL, and Turley CP (1987) Alteration of phenytoin binding by glycosylation of albumin in IDDM. Diabetes 36(4):505-509.
57. Kessler KM, Kissane B, Cassidy J, Pefkaros KC, Kozlovskis P, Hamburg C, and Myerburg RJ (1984) Dynamic variability of binding of antiarrhythmic drugs during the evolution of acute myocardial infarction. Circulation 70:472-478.
58. Koj A (1974) Hormonal regulation of protein synthesis of the acute phase. Folia Med Cracov 16(1): 131.
59. Kongstad L, Moller AD, and Grande PO (1999) Reflection coefficient for albumin and capillary fluid permeability in cat calf muscle after traumatic injury. Acta Physiol Scand 165(4):369-377.
60. Kornguth ML, Monson RA, and Kumin CM (1974) The binding of antibiotics to soluble protein from the rat liver. J Infect Dis 129:552-558.
61. Kotsiou A, Anagnostou M, Mourouzis C, Rallis G, Chantzi Ch, and Tesseromatis C (2006) Impact of experimental trauma and niflumic acid administration on antimicrobials' concentration in serum and mandible of rats. J Musculoskelet Neuronal Interact 6(3):242-246.
62. Kotsiou A, Diamanti E, Potamianou A, Parara H, Vovou J, Perisanidis C, and Tesseromatis C (2008) Anticoagulantinduced changes on antibiotic concentrations in the serum and bones. Eur J Drug Metab Pharmacokinet 33(3):173-179.
63. Kotsiou A, Tsamouri M, Anagnostopoulou S, Tzivras M, Vairactaris E, and Tesseomatis C (2006) H3 Propranolol serum levels following lidocaine administration in rats with CCL4 induced liver damage. Eur J Drug Metab Pharmacokinet 31(2):97-101.
64. Kratochwil NA, Huber W, Müller F, Kansy M, and Gerber PR (2002) Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol 64(9):1355-1374.
65. Kurz H and Fichtl B (1983) Binding of drugs to tissues. Drug Metab Rev 14:467-510.
66. Kurz H, Trunk H, and Weitz B (1977) Evaluation of methods to determine protein-binding of drugs. Equilibrium dialysis, ultrafiltration, ultracentrifugation, gel filtration. Arzneimittelforschung 27(7):1373-1380.
67. Larsson B and Tjälve H (1979) Studies on the mechanism of drugbinding to melanin. Biochem Pharmacol 28(7):1181-1187.
68. Láznícek M and Senius KE (1986) Protein binding of tolfenamic acid in the plasma from patients with renal and hepatic disease. Eur J Clin Pharmacol 30(5):591-596.
69. Levy RH (1984) Moreland TA Rationale for monitoring free drug levels. Clin Pharmacokinet 9(Suppl. 1):1-9.
70. Lima JJ, MacKichan JJ, Libertin N, and Sabino J (1983) Influence of volume shifts on drug binding during equilibrium dialysis: correction and attenuation. J Pharmacokinet Biopharm 11(5):483-498.
71. Lyoo IK and Renshaw PF (2002) Magnetic resonance spectroscopy: current and future applications in psychiatric research. Biol Psychiatry 51:195-207.
72. MacKichan JJ (1984) Pharmacokinetic consequences of drug displacement from blood and tissues proteins. Clin Pharmacokinet 9(Suppl. 1):32-41.
73. Majithia V and Geraci SA (2007) Rheumatoid arthritis: diagnosis and management. Am J Med 120(11):936-939.
74. Mendel CM (1989) Modeling thyroxine transport to liver: rejection of the "enhanced dissociation" hypothesis as applied to thyroxine. Am J Physiol 257(5Pt 1): E764-E771.
75. Miller AK, Adir J, and Vestal RE (1978) Tolbutamide binding to plasma proteins of young and old human subjects. J Pharm Sci 67(8):1192-1193.
76. Mitani GM, Steinberg I, Lien EJ, Harrison EC, and Elkayam U (1987) The pharmacokinetics of antiarrhythmic agents in pregnancy and lactation. Clin Pharmacokinet 12(4):253-291.
77. Moehler M, Dimitrakopoulou-Strauss A, Gutzler F, Raeth U, Strauss LG, and Stremmel W (1998) 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer 83:245-253.
78. Morgan DJ, Koay BB, Paull JD (1982) Plasma protein binding of etidocaine during pregnancy and labour. Eur J Clin Pharmacol 22:451-457.
79. Móller M (2000) Microdialysis in clinical drug delivery studies. Adv Drug Deliv Rev 45:255-269.
80. Olsen H, Andersen A, Nordbø A, Kongsgaard UE, and Børmer OP (2004) Pharmaceutical-grade albumin: impaired drug-binding capacity in vitro. BMC Clin Pharmacol 4:4.
81. Pacifici GM, Viani A, Taddeucci-Brunelli G, Rizzo G, Carrai M, and Schulz HU (1986) Effects of development, aging, and renal and hepatic insufficiency as well as hemodialysis on the plasma concentrations of albumin and alpha 1-acid glycoprotein: implications for binding of drugs. Ther Drug Monit 8(3):259-263.
82. Perucca E and Crema A (1982) Plasma protein binding of drugs in pregnancy. Clin Pharmacokinet 7(4):336-352.
83. Petersen CE, Ha C-E, Curry S, and Bhagavan NV (2002) Probing the structure of the warfarin-binding site on human serum albumin using site-directed mutagenesis. Proteins 47:116-125.
84. Petitpas I, Bhattacharya AA, Twine S, East M, and Curry S (2001) Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I. J Biol Chem 276:22804-22809.
85. Petitpas I, Grüne T, Bhattacharya AA, and Curry S (2001) Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. J Mol Biol 314:955-960.
86. Petitpas I, Petersen CE, Ha CE, Bhattacharya AA, Zunszain PA, Ghuman J, et al. (2003) Structural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemia. Proc Natl Acad Sci USA 100:6440-6445.
87. Philip A (1989) Mackowiak influence of fever on pharmacokinetics. Rev Infect Dis 11(5):804-807.
88. Piafsky KM, Borgá O, Odar-Cederlöf I, Johansson C, and Sjöqvist F (1978) Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med 299(26):1435-1439.
89. Reidenberg MM and Drayer DE (1984) Alteration of drugprotein binding in renal disease. Clin Pharmacokinet 9 (Suppl. 1):18-26.
90. Rolan PE (1994) Plasma protein binding displacement interactions-why are they still regarded as clinically important? Br J Clin Pharmacol 37(2):125-128.
91. Ronchera-Oms CL, Tormo C, Ordovas JP, Abad J, and Jimenez NV (1995) Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutrition. J Clin Pharm Ther 20(5):253-258.
92. Rowland M and Gupta SK (1987) Cyclosporin-phenytoin interaction: re-evaluation using metabolite data. Br J Clin Pharmacol 24(3):329-334.
93. Rowland N and Irving J (1984) Towards a rationalization of counselling in general practice. J R Coll Gen Pract 34(269):685-687.
94. Ruiz-Cabello F and Erill S (1984) Abnormal serum protein binding of acidic drugs in diabetes mellitus. Clin Pharmacol Ther 36(5):691-695.
95. Ruprah M, Perucca E, and Richens A (1980) Decreased serum protein binding of phenytoin in late pregnancy. Lancet 2(8189):316-317.
96. Sakai T, Yamasaki K, Sako T, Kragh-Hansen U, Suenaga A, and Otagiri M (2001) Interaction mechanism between indoxyl sulfate, a typical uremic toxin bound to site II, and ligands bound to site I of human serum albumin. Pharm Res 18:520-524.
97. Saleem A, Brown GD, Brady F, et al. (2003) Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 63:2409-2415.
98. Sansom LN and Evans AM (1995) What is the true clinical significance of plasma protein binding displacement interactions? Drug Saf 12(4):227-233.
99. Saranteas T, Mourouzis C, Koumoura F, and Tesseromatis C (2003) Effects of propranolol or paracetamol on lidocaine concentrations in serum and tissues. J Oral Maxillofac Surg 61(5):604-607.
100. Saranteas T, Mourouzis C, Dannis C, Alexopoulos C, Lolis E, and Tesseromatis C (2004) Effect of various stress models on lidocaine pharmacokinetic properties in the mandible after masseter injection. J Oral Maxillofac Surg 62(7):858-862.
101. Saranteas T, Tesseromatis C, Potamianou A, Mourouzis C, and Varonos D (2002) Stress-induced lidocaine modification in serum and tissues. Eur J Drug Metab Pharmacokinet 27(4):229-232.
102. Schuhmann G, Fichtl B, and Kurz H (1987) Prediction of drug distribution in vivo on the basis of in vitro binding data. Biopharm Drug Dispos 8(1):73-86.
103. Simard JR, Zunszain PA, Ha C-E, Yang JS, Bhagavan NV, Petitpas I, et al. (2005) Locating high-affinity fatty acidbinding sites on albumin by x-ray crystallography and NMR spectroscopy. Proc Natl Acad Sci USA 102:17958-17963.
104. Simard RJ, Zunszain AP, Hamilton AJ, and Curry S (2006) Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis. J Mol Biol 361(2):336-351.
105. Skipski VP, Barclay M, Barclay RK, Fetzer VA, Good JJ, and Archibald FM (1967) Lipid composition of human serum lipoproteins. Biochem J 104(2):340-352.
106. Soltys BJ and Hsia JC (1978) Steroid modulation of human serum albumin binding properties: a spin label study. J Biol Chem 253(12):4266-4269.
107. Somani P, Simon V, Gupta RK, King P, Shapiro RS, and Stockard H (1984) Lorcainide kinetics and protein binding in patients with end-stage renal disease. Int J Clin Pharmacol Ther Toxicol 22(3):121-125.
108. Speight TM and Holford NHG (1997) Avery's Drug Treatment. 4th ed. Adis International, Barcelona, p. 1647.
109. Sudlow G, Birkett DJ, and Wade DN (1975) The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol 11(6):824-832.
110. Suzuki T, Kato Y, Sasabe H, Itose M, Miyamoto G, and Sugiyama Y (2002) Mechanism for the tissue distribution of grepafloxacin, a fluoroquinolone antibiotic, in rats. Drug Metab Dispos 30(12):1393-1399.
111. Tawara S, Matsumoto S, Matsumoto Y, Kamimura T, and Goto S (1992) Structure-binding relationship and binding sites of cephalosporins in human serum albumin. J Antibiot 45(8):1346-1357.
112. Tesseromatis C and Alevizou A (2008) The role of the proteinbinding on the mode of drug action as well the interactions with other drugs. Eur J Drug Metab Pharmacokinet 33(4):225-230.
113. Tesseromatis C, Fichtl B, and Kurz H (1987) Binding of non-steroid anti-inflammatory drugs and warfarin to liver tissue of rabbits in vitro. Eur J Drug Metab Pharmacokinet 12(3):161-167.
114. Tesseromatis C, Kotsiou A, Tsagataki M, Tigka E, Vovou J, Alevizou A, Perisanidis C, Saranteas T, Karakitsos D, Karabinis A, and Kostopanagiotou G (2007) In Vitro binding of lidocaine to liver tissue under the influence of propranolol: another mechanism of interaction? Eur J Drug Metab Pharmacokinet 32(4):213-217.
115. Tesseromatis C, Kotsiou A, et al. (2004) Light induced changes in quinilone levels in rat serum and tissues. Eur J Drug Metab Pharmacokinet 29(4):231-233.
116. Tesserommatis C, Saranteas T, Chatzijanni E, Anagnostopoulou S, Cotsiou A, and Chatzi C (2003) Modifications of clonidine binding to rabbit liver protein under the influence of nonsteroid-anti-inflammatory drugs in vitro. Eur J Drug Metab Pharmacokinet 28(3):245-247.
117. Tesseromatis C, Trichilis A, Tsivos E, Messari J, Triantaphyllidis H, and Varonos DD (2001) Does stress influence ampicillin concentration in serum and tissues? Eur J Drug Metab Pharmacokinet 26(3):167-171.
118. Tesserommatis C, Tsopanakis C, Symeonoglou G, Loukissa M, Kouvarou E, and Varonos DD (1996) How harmless is FFA enhancement? Eur J Drug Metab Pharmacokinet 21(3): 213.
119. Tesserommatis C, Tsopanakis C, and Varonos D (1988) Changes in serum lipids with the presence of various factors. Beitr Infusionsther 23:195-197.
120. Tigka E, Daskala I, Rallis G, Anagnostopoulou S, and Tesseromatis C (2005) Adjuvant arthritis-induced changes on ampicillin binding in serum and tissues under the influence of nonsteroidal anti-inflammatory drugs in rats. Eur J Drug Metab Pharmacokinet 30(4):235-241.
121. Tillement JP, Lhoste F, and Giudicelli JF (1978) Diseases and drug protein binding. Clin Pharmacokinet 3(2):144-154.
122. Tiula E and Elfving S (1987) Serum protein binding of phenytoin, diazepam and propranolol in age-related decrease in renal function. Ann Clin Res 19(3):163-169.
123. Tiula E and Neuvonen PJ (1986) Effect of total drug concentration on the free fraction in uremic sera. Ther Drug Monit 8(1):27-31.
124. Tozer TN, Gambertoglio JG, Furst DE, Avery DS, and Holford NH (1983) Volume shifts and protein binding estimates using equilibrium dialysis application to prednisolone binding in humans. J Pharm Sci 72(12):1442-1446.
125. Trichilis A, Saranteas T, Potamianou A, Mourouzis C, and Tesseromatis C (2003) Quinolone levels in serum and maxillofacial tissues under ibuprofen co-administration following surgical trauma. J Musculoskelet Neuronal Interact 3(2):170-175.
126. Trichilis A, Tesserommatis C, and Varonos D (2000) Changes in serum levels of quinolones in rats under the influence of experimental trauma. Eur J Drug Metab Pharmacokinet 25(2):73-78.
127. Tsivou E, Melakopoulos I, Kotsiou A, Anagnostopoulou S, and Tesseromatis C (2005) Alterations in cephalosporin levels in the serum and mandible of hyperlipaedemic rats after coadministration of ibuprofen. Eur J Drug Metab Pharmacokinet 30(3):171-174.
128. Tsopanakis C and Tesserommatis C (1991) Cold swimming stress: effects on serum lipids, lipoproteins and LCAT activity in male and female rats. Pharmacol Biochem Behav 38(4):813-816.
129. Tsutsumi Y, Maruyama T, Takadate A, Goto M, Matsunaga H, and Otagiri M (1999) Interaction between two dicarboxylate endogenous substances, bilirubin and an uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, on human serum albumin. Pharm Res 16:916-923.
130. Tucker GT, Bax ND, Lennard MS, Al-Asady S, Bharaj HS, and Woods HF (1984) Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine. Br J Clin Pharmacol 17(Suppl 1): 21S-28S.
131. Viani A, Rizzo G, Carrai M, and Pacifici GM (1992) The effect of ageing on plasma albumin and plasma protein binding of diazepam, salicylic acid and digitoxin in healthy subjects and patients with renal impairment. Br J Clin Pharmacol 33(3):299-304.
132. Vorum H, Fisker K, and Honore B (1997) Palmitate and stearate binding to human serum albumin. Determination of relative binding constants. J Pept Res 49(4):347-354.
133. Vorum H and Honore B (1996) Influence of fatty acids on the binding of warfarin and phenprocoumon to human serum albumin with relation to anticoagulant therapy. J Pharm Pharmacol 48(8):870-875.
134. Vorum H, Jorgensen HR, and Brodersen R (1993) Variation in the binding affinity of warfarin and phenprocoumon to human serum albumin in relation to surgery. Eur J Clin Pharmacol 44(2):157-162.
135. Waller DG, Renwick AG, and Hillier K, eds. (2001) Medical Pharmacology and Therapeutics. Public W.B. Saunders Co Ltd, Philadelphia.
136. Wanwimorluk S, Birkett DJ, and Brooks PM (1983) Structural requirements for drug binding to site II on human serum albumin. Mol Pharmacol 24(3):458-463.
137. Wardell M, Wang Z, Ho JX, Robert J, Ruker F, Ruble J, and Carter DC (2002) The atomic structure of human methemalbumin at 1.9 AA. Biochem Biophys Res Commun 291:813-819.
138. Webb D, Buss DC, Fifield R, Bateman DN, and Routledge PA (1986) The plasma protein binding of metoclopramide in health and renal disease. Br J Clin Pharmacol 21(3):334-336.
139. Weisiger RA (1985) Dissociation from albumin: a potentially ratelimiting step in the clearance of substances by the liver. Proc Natl Acad Sci USA 82(5):1563-1567.
140. Wierzba K, Sugiyama Y, Okudaira K, Iga T, and Hanano M (1987) Tubulin as a major determinant of tissue distribution of vincristine. J Pharm Sci 76(12):872-875.
141. Wilting J, Hart BJ, and DeGier JJ (1980) The role of albumin conformation in the binding of diazepam to human serum albumin. Biochim Biophys Acta 626(2):291-298.
142. Wilting J, van der Giesen WF, Janssen LH, Weideman MM, Otagiri M, and Perrin JH (1980) The effect of albumin conformation on the binding of warfarin to human serum albumin. The dependence of the binding of warfarin to human serum albumin on the hydrogen, calcium, and chloride ion concentrations as studied by circular dichroism, fluorescence, and equilibrium dialysis. J Biol Chem 255(7):3032-3037.
143. Wosilait WD and Ryan MP (1979) The effects of oleic acid, tolbutamide, and oxyphenbutazone on the binding of warfarin by human serum albumin. Res Commun Chem Pathol Pharmacol 25(3):577-584.
144. Yacobi A and Levy G (1975) Comparative pharmacokinetics of coumarin anticoagulants. XIV: relationship between protein binding, distribution, and elimination kinetics of warfarin in rats. J Pharm Sci 64(10):1660-1664.
145. Yasuhara M and Levy G (1988) Kinetics of drug action in disease states XXVI: effect of fever on the pharmacodynamics of theophylline-induced seizures in rats. J Pharm Sci 77(7):569-570.
146. Zhang YZ, Xiang X, Mei P, Dai J, Zhang LL, and Liu Y (2009) Spectroscopic studies on the interaction of Congo red with bovine serum albumin. Spectrochim Acta A Mol Biomol Spectrosc 72(4):907-914.
147. Zou HH, Adedoyin A, and Wilkinson GR (1990) Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther 48(1):10-17.
148. Zunszain PA, Ghuman J, Komatsu T, Tsuchidia E, and Curry S (2003) Crystal structural analysis of human serum albumin complexed with hemin and fatty acid. BMC Struct Biol 3:6.